PA
PTGX icon

Parallel Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Parallel Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13K Buy
123
+14
+13% +$1.24K ﹤0.01% 2639
2025
Q4 		$9.52K Buy
109
+7
+7% +$573 ﹤0.01% 2627
2025
Q3 		$6.78K Buy
102
+5
+5% +$284 ﹤0.01% 2661
2025
Q2 		$5.36K Buy
97
+70
+259% +$3.36K ﹤0.01% 2719
2025
Q1 		$1.31K Hold
27
– – ﹤0.01% 3065
2024
Q4 		$1.04K Sell
27
-16
-37% -$698 ﹤0.01% 3104
2024
Q3 		$1.94K Buy
43
+16
+59% +$646 ﹤0.01% 2899
2024
Q2 		$936 Buy
+27
New +$791 ﹤0.01% 2976

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Parallel Advisors's PTGX Position: Q1 2026 in Review

Parallel Advisors increased its Protagonist Therapeutics (PTGX) stake by 13% in Q1 2026, buying an estimated $1.24K and bringing the position to 123 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #2639.

Parallel Advisors first reported a position in PTGX in Q2 2024 and has held it in 8 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Parallel Advisors held 123 shares of Protagonist Therapeutics worth $13K as of Q1 2026.
  • Parallel Advisors bought 14 Protagonist Therapeutics shares in Q1 2026, an estimated $1.24K.
  • Protagonist Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2639 holding.
  • Parallel Advisors first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.